Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial
Introduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carni...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2018-12-01
|
| Series: | Journal of Analytical Research in Clinical Medicine |
| Subjects: | |
| Online Access: | https://jarcm.tbzmed.ac.ir/PDF/JARCM_19782_20180118140326 |
| _version_ | 1818944749634060288 |
|---|---|
| author | Hamid Noshad Davoud Mohammadi Nejhad Parastou Hoseini Majid Montazer Behnaz Ghamari Farid Karkon Shayan |
| author_facet | Hamid Noshad Davoud Mohammadi Nejhad Parastou Hoseini Majid Montazer Behnaz Ghamari Farid Karkon Shayan |
| author_sort | Hamid Noshad |
| collection | DOAJ |
| description | Introduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carnitine combination versus atorvastatin alone on the lipid profile of hemodialyzed patients. Methods: In this clinical trial, 50 hemodialysis patients referred to the educational centres of Tabriz University of Medical Sciences, Tabriz, Iran, for haemodialysis were enrolled. Patients were randomly assigned into two groups. In the first group, patients were treated with carnitine (1000 mg three times daily) and atorvastatin (10-80 mg/day based on the baseline lipid profile of the patients) and in the second group, the patients were treated with atorvastatin alone for six months. The levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin before and after intervention were compared. The side effects of carnitine administration were also evaluated. Results: Results showed that TG, cholesterol, and LDL levels were significantly lower in the carnitine group compared to those in the other group at the end of study (P < 0.050). In addition, HDL and haemoglobin levels were significantly higher in the carnitine group in comparison to the other group (P < 0.050). No major side effects of carnitine were observed among the patients. Conclusion: The use of carnitine plus atorvastatin combination is an effective and safe method in the treatment of dyslipidemia in patients undergoing hemodialysis without imposing significant side effects. |
| first_indexed | 2024-12-20T07:48:10Z |
| format | Article |
| id | doaj.art-c5c98f00bb3e46fb9a81c3347ee2fdde |
| institution | Directory Open Access Journal |
| issn | 2345-4970 |
| language | English |
| last_indexed | 2024-12-20T07:48:10Z |
| publishDate | 2018-12-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | Journal of Analytical Research in Clinical Medicine |
| spelling | doaj.art-c5c98f00bb3e46fb9a81c3347ee2fdde2022-12-21T19:47:56ZengTabriz University of Medical SciencesJournal of Analytical Research in Clinical Medicine2345-49702018-12-016416517110.15171/jarcm.2018.027JARCM_19782_20180118140326Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trialHamid Noshad0Davoud Mohammadi Nejhad1Parastou Hoseini2Majid Montazer3Behnaz Ghamari4Farid Karkon Shayan5Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, IranStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Surgery, School of Medicine, Tabriz University of Medical Sciences, Tabriz, IranConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IranChronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IranIntroduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carnitine combination versus atorvastatin alone on the lipid profile of hemodialyzed patients. Methods: In this clinical trial, 50 hemodialysis patients referred to the educational centres of Tabriz University of Medical Sciences, Tabriz, Iran, for haemodialysis were enrolled. Patients were randomly assigned into two groups. In the first group, patients were treated with carnitine (1000 mg three times daily) and atorvastatin (10-80 mg/day based on the baseline lipid profile of the patients) and in the second group, the patients were treated with atorvastatin alone for six months. The levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin before and after intervention were compared. The side effects of carnitine administration were also evaluated. Results: Results showed that TG, cholesterol, and LDL levels were significantly lower in the carnitine group compared to those in the other group at the end of study (P < 0.050). In addition, HDL and haemoglobin levels were significantly higher in the carnitine group in comparison to the other group (P < 0.050). No major side effects of carnitine were observed among the patients. Conclusion: The use of carnitine plus atorvastatin combination is an effective and safe method in the treatment of dyslipidemia in patients undergoing hemodialysis without imposing significant side effects.https://jarcm.tbzmed.ac.ir/PDF/JARCM_19782_20180118140326CarnitineAtorvastatinHemodialysisDyslipidemia |
| spellingShingle | Hamid Noshad Davoud Mohammadi Nejhad Parastou Hoseini Majid Montazer Behnaz Ghamari Farid Karkon Shayan Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial Journal of Analytical Research in Clinical Medicine Carnitine Atorvastatin Hemodialysis Dyslipidemia |
| title | Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial |
| title_full | Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial |
| title_fullStr | Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial |
| title_full_unstemmed | Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial |
| title_short | Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial |
| title_sort | atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients a randomised clinical trial |
| topic | Carnitine Atorvastatin Hemodialysis Dyslipidemia |
| url | https://jarcm.tbzmed.ac.ir/PDF/JARCM_19782_20180118140326 |
| work_keys_str_mv | AT hamidnoshad atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial AT davoudmohammadinejhad atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial AT parastouhoseini atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial AT majidmontazer atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial AT behnazghamari atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial AT faridkarkonshayan atorvastatinandcarnitinecombinationversusatorvastatinaloneimpactsonthelipidprofileofhaemodialyzedpatientsarandomisedclinicaltrial |